Home
Concert Pharmaceuticals

Concert Pharmaceuticals Market Share Analysis for June 2026

creating newpossibilities for patients to livetheir lives

Health > Biotechnology and Pharmaceuticals

Domainconcertpharma.com

Year Founded2006

Employees51 - 200

Annual Revenue< $1M

Concert Pharmaceuticals

Concert Pharmaceuticals (including company regionals)

concertpharma.com

See more website traffic and engagement information

Total visits to Concert Pharmaceuticals's top domains

Understand Concert Pharmaceuticals market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Concert Pharmaceuticals's top domains

Analyze Concert Pharmaceuticals engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Concert Pharmaceuticals's top domains

See how Concert Pharmaceuticals keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Concert Pharmaceuticals top competitors by domain

Top similar sites in June 2026, ranked by their affinity

kingpharm.comCompany NameKing PharmaceuticalsEmployees1001 - 5000HQUnited States, Tennessee, BristolAnnual revenue--Total visits--Health > Biotechnology and Pharmaceuticals

Top technologies used by Concert Pharmaceuticals

These are the website technologies, by industry, used by Concert Pharmaceuticals top domains

Widget (5)

Twemoji

Email Services (2)

Microsoft Exchange Online

Social (2)

Instagram

Audio Video Media (1)

Vimeo

More Technologies

7

See all

News & Signals from Concert Pharmaceuticals

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMyrevital acquired Concertpharma for $576M on May 26th '23.Earlier this year, Sun Pharma also announced the completion of its acquisition of Concert Pharmaceuticals.

NewsIlumya acquired Concertpharma for $576M on Jan 26th '23.Sun Pharma this month acquired US-based Concert Pharmaceuticals for $576 million in cash aimed at accessing Concert’s experimental drug—Deuruxolitinib--a potential treatment of Alopecia Areata, a skin disease causing partial or complete loss of hair on the scalp and body.

NewsConcertpharma had issues with possible breaches of fiduciary duty and other violations of law on Jan 19th '23.Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Concert Pharmaceuticals, Inc. ("Concert" or the "Company") (NASDAQ: CNCE ), in connection with the proposed acquisition of the Company by Sun Pharmaceutical Industries Limited via tender offer.